P2Y14 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5103202-Each-of-1 | In Stock | ₹ 46,858.50 |
PIPA5103202 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,858.50
GST (18%): ₹ 8,434.53
Total Price: ₹ 55,293.03
Antigen
P2Y14
Classification
Polyclonal
Conjugate
Unconjugated
Gene
P2RY14
Gene Alias
A330108O13Rik; BPR105; G protein coupled receptor for UDP-glucose; G protein-coupled receptor 105; G protein-coupled receptor VTR 15-20; GPCR105; Gpr105; G-protein coupled receptor 105; KIAA0001; P2ry14; P2Y purinoceptor 14; P2Y(14) receptor; P2Y14; P2Y14 receptor; purinergic receptor P2Y, G-protein coupled, 14; purinergic receptor P2Y14; UDP-glucose receptor; VTR 15-20; VTR 15-20 receptor
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
140795, 171108, 9934
Content And Storage
-20°C
Form
Liquid
Applications
Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
O35881, Q15391, Q9ESG6
Gene Symbols
P2RY14
Immunogen
A synthesized peptide derived from human P2RY14(Accession Q15391), corresponding to amino acid residues A153-I203.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total GPR105
- GPR105 has been reported to be expressed in brain
- ESTs have been isolated from kidney, placenta, uterus, and heart/melanocyte/uterus libraries
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This "eturn-off"e activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.